ACTELION, CH0010532478

Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange

09.06.2017 - 17:48:25

GNW-News: Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange

  Aprocitentan   Endothelin receptor   Resistant hypertension

(ACT-132577) antagonist

  ACT-541468   Dual orexin receptor   Chronic insomnia


Phase 2

    Endothelin receptor   Vasospasm associated

Clazosentan antagonist with aneurysmal

subarachnoid hemorrhage

  Cenerimod   S1P(1) receptor modulator   Systemic lupus


Phase 1b   Lucerastat   Glucosylceramide synthase   Fabry disease


  ACT-246475   P2Y12 receptor antagonist   Acute coronary syndrome

  ACT-774312   CRTH2 receptor antagonist   Asthma and allergy


Phase 1

  ACT-539313   Selective orexin 1   Anxiety

receptor antagonist

  ACT-709478   T-type calcium channel   Epilepsy


Corporate Governance

Idorsia's Board of Directors comprises Jean-Pierre Garnier (Chairman), Robert

Bertolini (member, Chair Finance & Audit committee), Jean-Paul Clozel (member),

John J. Greisch (member, Chair Nominating, Governance & Compensation committee),

David Stout (member) and Herna Verhagen (member).

Idorsia's Executive Committee consists of Jean-Paul Clozel (Chief Executive

Officer), Guy Braunstein (Head of Global Clinical Development), Martine Clozel

(Chief Scientific Officer) and André C. Muller (Chief Financial Officer).

Indicative timetable of events

All dates listed below represent Idorsia's current expectations of the timing of

key events in connection with the listing of Idorsia shares and are subject to


Event Expected Date

Cut-off Date for entitlement to receive dividend in kind 13 June 2017

Ex-dividend date 14 June 2017

Record date 15 June 2017

Distribution of the Main Shares and Settlement 16 June 2017

Listing and First Day of Trading of the Main Shares on SIX 16 June 2017

Listing and First Day of Trading of the Authorized Shares on SIX 20 June 2017

The listing prospectus can be accessed by Actelion's shareholders via internet

on Actelion's website



Notes to the Editor

Actelion's financial statements for the first quarter of 2017

In order to prepare the pro-forma financial information for Idorsia, the first

quarter financial statements for Actelion were used as a baseline. They can be

found in the financial archive at:

Collaboration Agreement with Janssen Biotech, Inc.

Idorsia and Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, have

entered into a Collaboration Agreement giving Janssen Biotech, Inc. the option

to collaborate with Idorsia to jointly develop and solely commercialize

aprocitentan (ACT-132577) and any of its derivative compounds or products.

Aprocitentan is being investigated for use in resistant hypertension and has

completed a dose-finding study in essential hypertension. Following the later of

the end of the Phase 2 study meeting with the FDA or receipt by Janssen Biotech,

Inc. of a complete Phase 2 data package, Janssen Biotech, Inc. will have thirty

days to opt in to the collaboration by paying Idorsia a milestone payment of USD

230 million. In addition, under the terms of the Collaboration Agreement,

Janssen Biotech, Inc. will pay Idorsia royalties on products containing


Revenue Sharing Agreement with Johnson & Johnson

Idorsia Pharmaceuticals Ltd, J&J and Actelion Pharmaceuticals Ltd have entered

into a Revenue Sharing Agreement in respect of ponesimod and cadazolid. Under

the terms of the Revenue Sharing Agreement, if market authorization is obtained,

Idorsia Pharmaceuticals Ltd is entitled to receive quarterly payments of 8% of

the aggregate net sales of ponesimod and cadazolid products from Actelion

Pharmaceuticals Ltd. For each of ponesimod and cadazolid, payments will be made

under the Revenue Sharing Agreement for fifteen years from the latest launch of

a product containing ponesimod or cadazolid (as applicable) in (i) the United

States, (ii) Canada or (iii) any one of the United Kingdom, France, Germany,

Italy and Spain.

For further information please contact:

Andrew Weiss

Senior Vice President, Head of Investor Relations & Corporate Communications

Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil

+41 61 565 62 62

The above information contains certain "forward-looking statements", relating to

the company's business, which can be identified by the use of forward-looking

terminology such as "estimates", "believes", "expects", "may", "are expected

to", "will", "will continue", "should", "would be", "seeks", "pending" or

"anticipates" or similar expressions, or by discussions of strategy, plans or

intentions. Such statements include descriptions of the company's investment and

research and development programs and anticipated expenditures in connection

therewith, descriptions of new products expected to be introduced by the company

and anticipated customer demand for such products and products in the company's

existing portfolio. Such statements reflect the current views of the company

with respect to future events and are subject to certain risks, uncertainties

and assumptions. Many factors could cause the actual results, performance or

achievements of the company to be materially different from any future results,

performances or achievements that may be expressed or implied by such forward-

looking statements. Should one or more of these risks or uncertainties

materialize, or should underlying assumptions prove incorrect, actual results

may vary materially from those described herein as anticipated, believed,

estimated or expected.

Press release PDF:

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Actelion Pharmaceuticals Ltd via GlobeNewswire


Amazon wird sich schwarzärgern, aber …

… wir schenken Ihnen den Report „Börsenpsychologie - Markttechnik für Trader“ heute trotzdem kostenfrei. Normalerweise kostet der Report im Onlinehandel 39,99 Euro.

Sie können sich den genialen Report heute jedoch absolut kostenfrei sichern. Wir senden Ihnen den Report vollkommen KOSTENFREI zu.

Jetzt HIER klicken und dank richtigen Timing reich an der Börse werden!